edotreotide has been researched along with 68ga-dotanoc in 2 studies
| Studies (edotreotide) | Trials (edotreotide) | Recent Studies (post-2010) (edotreotide) | Studies (68ga-dotanoc) | Trials (68ga-dotanoc) | Recent Studies (post-2010) (68ga-dotanoc) |
|---|---|---|---|---|---|
| 206 | 34 | 86 | 183 | 7 | 157 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dutta, R; Jindal, T; Kumar, A; Kumar, R | 1 |
| Breeman, WA; de Blois, E; Konijnenberg, M; Krenning, EP; Kwekkeboom, DJ; Sze Chan, H | 1 |
1 review(s) available for edotreotide and 68ga-dotanoc
| Article | Year |
|---|---|
(68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives.
Topics: Forecasting; Gallium Radioisotopes; Humans; Molecular Structure; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Peptides; Positron-Emission Tomography; Radioactivity; Radionuclide Generators; Radiopharmaceuticals; United States | 2011 |
1 other study(ies) available for edotreotide and 68ga-dotanoc
| Article | Year |
|---|---|
Role of 68Ga-DOTATOC PET/CT in carcinoids.
Topics: Carcinoid Tumor; Cushing Syndrome; Humans; Lung Neoplasms; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |